tucatinib,olaparib,vemurafenib,larotrectinib,trastuzumab,nivolumab,regorafenib,cobimetinib,temsirolimus,sunitinib,futibatinib,pertuzumab,entrectinib,abemaciclib,palbociclib,pembrolizumab,ipilimumab,talazoparib,atezolizumab
eli lilly,astrazeneca,seagen,bms,roche,merck,bayer,pfizer,otsuka
['tapur']
 #tapur abstracts presented this morning. 
I am a medical oncologist and the Principal Investigator of the American Society of Clinical Oncology TAPUR study. Tweets are my own.